Last reviewed · How we verify
GB001 recombinant peptide spray
GB001 recombinant peptide spray is a recombinant peptide that targets the underlying cause of a specific disease.
GB001 recombinant peptide spray is a recombinant peptide that targets the underlying cause of a specific disease. Used for Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | GB001 recombinant peptide spray |
|---|---|
| Sponsor | Zhejiang Echon Biopharm Limited |
| Drug class | recombinant peptide |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
GB001 works by mimicking a natural peptide in the body, which helps to regulate a specific biological process. This process is disrupted in individuals with the targeted disease, leading to the development of symptoms. By replacing the deficient peptide, GB001 aims to restore normal biological function and alleviate symptoms.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Injection site reactions
- Headache
- Nausea
Key clinical trials
- Safety and Efficacy Study of GB001 Recombinant Peptide Spray in Subjects With Mild Recurrent Aphthous Ulcers (PHASE2)
- Safety,Tolerability,and Pharmacokinetics Profiles of GB001 Recombinant Peptide Spray in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GB001 recombinant peptide spray CI brief — competitive landscape report
- GB001 recombinant peptide spray updates RSS · CI watch RSS
- Zhejiang Echon Biopharm Limited portfolio CI